.png){kind=icon}
返回
Soft Tissue Sarcoma, Version 2.2022
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2022.0035.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic char-acteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of pa-tients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, eval-uation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guide-lines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recom-mendations, and reviews the evidence to support the guidelines recommendations. J Natl Compr Canc Netw 2022;20(7):815???833 doi: 10.6004/jnccn.2022.0035
Keyword:
RANDOMIZED PHASE-II
PREOPERATIVE RADIATION-THERAPY
DOXORUBICIN PLUS IFOSFAMIDE
ELECTRON-BEAM RADIOTHERAPY
HIGH-RISK EXTREMITY
NEOADJUVANT CHEMOTHERAPY
EUROPEAN-ORGANIZATION
RETROPERITONEAL SARCOMA
ADJUVANT CHEMOTHERAPY
1ST-LINE TREATMENT
期刊
J
IF:
16.4
论文数:
2.8K
被引数:
1.5W
机构
查看更多机构
引用论文
分享收藏Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis多西他赛联合吉西他滨133晚期软组织肉瘤的回顾性分析
OAAI
OAAI分享收藏REGOSARC: Regorafenib Versus Placebo in Doxorubicin-Refractory Soft-Tissue Sarcoma-A Quality-Adjusted Time Without Symptoms of Progression or Toxicity AnalysisREGOSARC: Regorafenib与安慰剂在阿霉素难治性软组织肉瘤中的比较-无进展症状或毒性分析的质量调整时间.png)
CANCEROAAI
CANCERIF5.1
OAAI分享收藏 查看更多内容